Patent · US Active

Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes

US9517261B2 · kind B2 · utility

3Cited by

1References

17Claims

0Family size

Assignee

Deutsches Krebsforschungszentrum · DE

Inventors

Regina Feederle · Munich, DE
Sophia Hundt · Heidelberg, DE
Henri-Jacques Delecluse · Heidelberg, DE

Key dates

Filing date	Dec 28, 2012
Grant date	Dec 13, 2016
Priority date	—
Expiry date	Jan 28, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/204
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing the EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising the EB-VLPs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.